全文获取类型
收费全文 | 42532篇 |
免费 | 4241篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 374篇 |
儿科学 | 1444篇 |
妇产科学 | 1155篇 |
基础医学 | 5996篇 |
口腔科学 | 794篇 |
临床医学 | 5256篇 |
内科学 | 7475篇 |
皮肤病学 | 603篇 |
神经病学 | 3702篇 |
特种医学 | 1158篇 |
外国民族医学 | 3篇 |
外科学 | 5015篇 |
综合类 | 782篇 |
一般理论 | 106篇 |
预防医学 | 5777篇 |
眼科学 | 592篇 |
药学 | 3012篇 |
中国医学 | 107篇 |
肿瘤学 | 3468篇 |
出版年
2023年 | 342篇 |
2022年 | 215篇 |
2021年 | 1071篇 |
2020年 | 774篇 |
2019年 | 1174篇 |
2018年 | 1279篇 |
2017年 | 907篇 |
2016年 | 983篇 |
2015年 | 1070篇 |
2014年 | 1409篇 |
2013年 | 1948篇 |
2012年 | 2961篇 |
2011年 | 2928篇 |
2010年 | 1561篇 |
2009年 | 1325篇 |
2008年 | 2302篇 |
2007年 | 2280篇 |
2006年 | 2338篇 |
2005年 | 2175篇 |
2004年 | 1960篇 |
2003年 | 1735篇 |
2002年 | 1617篇 |
2001年 | 908篇 |
2000年 | 905篇 |
1999年 | 826篇 |
1998年 | 412篇 |
1997年 | 304篇 |
1996年 | 296篇 |
1995年 | 309篇 |
1994年 | 264篇 |
1993年 | 244篇 |
1992年 | 607篇 |
1991年 | 519篇 |
1990年 | 522篇 |
1989年 | 457篇 |
1988年 | 437篇 |
1987年 | 444篇 |
1986年 | 432篇 |
1985年 | 408篇 |
1984年 | 326篇 |
1983年 | 264篇 |
1982年 | 220篇 |
1981年 | 216篇 |
1980年 | 185篇 |
1979年 | 288篇 |
1978年 | 225篇 |
1977年 | 180篇 |
1974年 | 199篇 |
1973年 | 189篇 |
1972年 | 196篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
1.
2.
3.
Hendrik Kröning Thomas Göhler Thomas Decker Marc Grundeis Georgi Kojouharoff Jörg Lipke Dieter Semsek Enno Moorahrend Annette Sauer Harald-Robert Bruch Rüdiger Liersch Arnd Nusch Ursula Vehling-Kaiser Manfred Welslau Ralf Grunewald Hanns-Detlev Harich Marcel Stephany Jens Uhlig Rebecca de Buhr Melanie Frank Cathrin Hogrefe Norbert Marschner Karin Potthoff Frank Hartmann Timo Reisländer Ingo Schwaner 《International journal of cancer. Journal international du cancer》2023,153(6):1227-1240
The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial. Primary endpoint was overall survival (OS). Secondary objectives included progression-free survival (PFS), safety, and quality of life (QoL). Subgroups comprised patients with good (<3 metastatic sites at inclusion, ≥18 months from diagnosis of first metastasis to inclusion) or poor (remaining patients) prognostic characteristics (GPC/PPC). GPC without liver metastases was considered best prognostic characteristics (BPC). In total, 307 eligible patients (pretreated or not suitable for other available therapies) were treated with FTD/TPI. Overall, median [95%-CI] OS was 7.4 months [6.4-8.6], median PFS was 2.9 months [2.8-3.3]. In BPC (n = 65) and GPC (n = 176) compared to PPC (n = 124) subgroup, median OS (13.3 [9.1-17.6] vs 8.9 [7.6-9.8] vs 5.1 [4.4-7.0] months) and median PFS (4.0 [3.3-5.3] vs 3.4 [3.0-3.7] vs 2.6 [2.4-2.8] months) were longer. Patient-reported QoL, assessed by validated questionnaires (EQ-5D-5L, PRO-CTCAE), was stable throughout FTD/TPI treatment. Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13.0%), leukopenia (7.5%), and anemia (5.2%). Altogether, palliative FTD/TPI therapy in patients with pretreated mCRC was associated with prolonged survival, delayed progression, maintained health-related QoL, and manageable toxicity. Low metastatic burden and indolent disease were favorable prognostic factors for survival. TACTIC confirms the effectiveness and safety of FTD/TPI, highlighting its value in routine clinical practice. 相似文献
4.
Marc Evans MD Susanne Engberg MD Mads Faurby MSc João Diogo Da Rocha Fernandes MSc Pollyanna Hudson MSc William Polonsky PhD 《Diabetes, obesity & metabolism》2022,24(3):377-390
We designed a systematic literature review to identify available evidence on adherence to and persistence with antidiabetic medication in people with type 2 diabetes (T2D). Electronic screening and congress searches identified real-world noninterventional studies (published between 2010 and October 2020) reporting estimates of adherence to and persistence with antidiabetic medication in adults with T2D, and associations with glycaemic control, microvascular and/or macrovascular complications, hospitalizations and healthcare costs. Ninety-two relevant studies were identified, the majority of which were retrospective and reported US data. The proportions of patients considered adherent (median [range] 51.2% [9.4%-84.3%]) or persistent (median [range] 47.7% [16.9%-94.0%]) varied widely across studies. Multiple studies reported an association between greater adherence/persistence and greater reductions in glycated haemoglobin levels. Better adherence/persistence was associated with fewer microvascular and/or macrovascular outcomes, although there was little consistency across studies in terms of which outcomes were improved. More adherent and more persistent patients were typically less likely to be hospitalized or to have emergency department visits/admissions and spent fewer days in hospital annually than less adherent/persistent patients. Greater adherence and persistence were generally associated with lower hospitalization costs, higher pharmacy costs and lower or budget-neutral total healthcare costs compared with lower adherence/persistence. In conclusion, better adherence and persistence in people with T2D is associated with lower rates of microvascular and/or macrovascular outcomes and inpatient hospitalization, and lower or budget-neutral total healthcare expenditure. Education and treatment strategies to address suboptimal adherence and persistence are needed to improve clinical and economic outcomes. 相似文献
5.
6.
Alexander D. Sherry MD Kelsey L. Corrigan MD MPH Ramez Kouzy MD Joseph Abi Jaoude MD Yumeng Yang MS Roshal R. Patel MD Douglas J. Totten MD MBA Neil B. Newman MD MS Prajnan Das MD MS MPH Cullen Taniguchi MD PhD Bruce Minsky MD Rebecca A. Snyder MD MPH C. David Fuller MD PhD Ethan Ludmir MD 《Cancer》2023,129(21):3430-3438
7.
8.
ChiaChi Lin TsaiSheng Yang ChiaJui Yen Rebecca Cheng Junjun Liu Chiun Hsu 《The oncologist》2020,25(12)
Lessons Learned
- The combination of ramucirumab (8 mg/kg intravenous, day 1 every 2 weeks) and FOLFOX4 as first‐line treatment in patients with advanced hepatocellular carcinoma (HCC) was not sufficiently tolerated.
- Preliminary efficacy data suggest that the combination may provide clinical benefit to patients with HCC.
- Dose modification and patient selection should be considered for the future development of ramucirumab plus FOLFOX chemotherapy for advanced HCC.
9.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721
10.
Kirsty Liddiard Sally Whitney Katy Evans Lucy Watts Emma Vogelmann Ruth Spurr Carrie Aimes Katherine Runswick‐Cole Dan Goodley 《Sociology of health & illness》2019,41(8):1473-1487
This paper is built upon an assumption: that social theory can be generated through a meaningful engagement with a co‐researcher group of disabled young people. Our co‐researchers are theoretical provocateurs and theorists in their own right who, through their activism and writing, are challenging us to reconsider the meaning of life, death and disability. Their work on our funded Economic and Social Research Council (ESRC) project has enabled us to consider the promise and potential of humanist and posthuman epistemologies, theories, methodologies, interventions and activisms. The paper introduces the research, the authors of this paper (academics and co‐researchers) and then explores three layers of analysis that work the edges of posthuman thinking; sovereign and assembled selves; affects and desires; mourning and affirmation. We conclude by asserting that as a research team we are engaging with a DisHuman approach to theory and activism: one that blends the pragmatics of humanism with posthuman possibilities. 相似文献